Join Glenn Hunzinger and Dan Farrell as they discuss why 2026 could mark a rebound year for health services dealmaking—driven by higher-quality assets, improving market conditions, and the growing role of technology and AI. They explore how investors are rethinking value creation, from tech-enabled care models to carve-outs and IPOs.

Discussion highlights:

• Stronger earnings, cash flows, and tech-enabled platforms are drawing buyers back
• AI is shifting from a value enhancer to a key driver of margins and valuation
• Carve-outs remain active as health systems and corporates divest non-core assets
• Investors are targeting opportunities across specialties, home-based care, and AI-enabled platforms
• Reopening IPO markets and improved exit options are boosting confidence for 2026

Speakers:
Glenn Hunzinger, US Health Industries Leader, PwC
Dan Farrell, US Health Services Deals Leader, PwC

Linked materials:

• https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html
• https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html
• https://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as Glenn Hunzinger and Roel van den Akker share their outlook for pharmaceutical and life sciences dealmaking in 2026. They discuss improving market conditions, innovation driven growth, and how upcoming loss of exclusivity is shaping deal strategy.

Discussion highlights:

• Strong innovation, healthy balance sheets, and improving capital markets support a positive outlook for 2026
• M&A is expected to remain precision-led and asset-focused, centered on differentiated science and key therapeutic areas
• Accelerating loss of exclusivity (2026–2029) is increasing reliance on external innovation
• Mid-sized deals have dominated, but clearer policy and better financing may enable larger strategic transactions
• As innovation globalizes, companies are sourcing assets more deliberately worldwide, with the US remaining a core life sciences hub

Speakers:
Glenn Hunzinger, US Health Industries Leader, PwC
Roel van den Akker, US Pharmaceutical & Life Sciences Deals Leader, PwC

Linked Materials:

• https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html
• https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html
• https://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

What will healthcare look like a decade from now? Host Glenn Hunzinger is joined by Greg Rotz, Pharmaceutical and Life Sciences Advisory Leader and Thom Bales, Principal, Health Services Advisory Leader, as they dive into the future of health—one driven by smarter tech, empowered consumers, and breakthrough science. From reimagining chronic care to building new business models, discover the mindset, partnerships, and capabilities that will define the next era of healthcare.

Discussion highlights:

• A trillion-dollar shift: who gains and who falls behind
• The rise of the super consumer and personalized care
• Why experience design will become core to life sciences
• How health orgs can prepare with “no regrets” strategic moves
• Collaborating across the ecosystem to drive faster, better, cheaper care

Speakers:

• Glenn Hunzinger, US Health Industries Leader, PwC
• Greg Rotz, Pharmaceutical and Life Sciences Advisory Leader, PwC
• Thom Bales, Health Services Advisory Leader, PwC

Linked materials:

From breaking point to breakthrough: the $1 trillion opportunity to reinvent healthcare

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.